GSK-backed Liq­uidia takes a seat at the IPO ta­ble, look­ing for a $57.5M stake to take on Unit­ed Ther­a­peu­tics

Liq­uidia Tech­nolo­gies be­lieves the time is ripe to go pub­lic, ask­ing in­vestors to sign on for a $57.5 mil­lion IPO de­signed to get them through a late-stage study of a “new and im­proved” way to de­liv­er an in­haled drug to treat pul­monary ar­te­r­i­al hy­per­ten­sion — and take down Unit­ed Ther­a­peu­tics’ stan­dard of care Ty­va­so in the process.

The biotech — which has a tech­nol­o­gy col­lab­o­ra­tion in place with Glax­o­SmithK­line — has been work­ing on per­fect­ing its drug par­ti­cle tech in de­vel­op­ing LIQ861, an in­haled form of tre­pros­tinil. Their boast is that they know how to con­sis­tent­ly make the well known drug in a way that can be de­liv­ered in a dis­pos­able in­haler. And that, they say, would put Ty­va­so and its neb­u­liz­er — which earned $404 mil­lion last year — to shame.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.